AKT1 and prostate carcinoma: Additionally, by integrating multi-omics data, researchers can uncover how prostate cancer cells develop resistance to AR-targeted therapies by activating alternative pathways such as PI3K/Akt, providing crucial insights for designing more effective combination therapies.